Xalnesiran
Xalnesiran (RO7445482) is a small interfering RNA molecule that targets a conserved region of the
hepatitis B virus (HBV) genome. Xalnesiran can be used for the research of chronic hepatitis B infection.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2538784-48-2
- Formel: C664H871F17N231O415P57S6
- Molecular Weight:21009.15
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
In Vitro
Chemical Information
-
CAS. Nr. 2538784-48-2
-
Molecular Weight 21009.15
-
Formel C664H871F17N231O415P57S6
-
SMILES
[Xalnesiran]
-
Synonyms
RO7445482
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Reinheit & Dokumentation
Verweise
[1]. Hui RW, et al. Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies. Hepatol Int. 2025;19(4):704-719. [Content Brief]
[2]. Tang Q, et al. Xalnesiran with or without an immunomodulator in chronic hepatitis B: still a challenge in functional cure. Hepatobiliary Surg Nutr. 2025 Apr 1;14(2):348-350. [Content Brief]
[3]. Hou J, et al. Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B. N Engl J Med. 2024 Dec 5;391(22):2098-2109. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)